CAR T therapy has delivered remarkable results for people with certain blood cancers—sometimes sending aggressive disease into deep remission after a single infusion. But today, only about 20% of eligible patients can actually get it. In this episode, sponsored by our partners at Allogene Therape...
CAR T therapy has delivered remarkable results for people with certain blood cancers—sometimes sending aggressive disease into deep remission after a single infusion. But today, only about 20% of eligible patients can actually get it. In this episode, sponsored by our partners at Allogene Therapeutics, Katie sits down with Dr. Zachary Roberts to unpack why access remains so limited and how new allogeneic (or “off-the-shelf”) CAR T therapies could be a turning point. They discuss how using healthy donor T-cells, rather than a patient’s own, may help bypass manufacturing hurdles and bring advanced treatment to more oncologists, more hospitals, and more communities. To learn more, visit Alpha3trial.com. #AllogenePartner
See omnystudio.com/listener for privacy information.